Description: This exclusive meeting focuses exclusively on developing multi-specific cell engaging therapies in liquid and solid tumor indications
Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2024 event, please get in touch at [email protected]
Tecytinib’s approval in 2022 fuelled the mentality that 2023 is the year of cell engager ! Bispecifics have led the way and liquid tumors have been hit hard. Now Immunocore and others are starting to take the fight to solid tumors .
The 5th Annual Cell Engager Summit returned this year dedicated to discovering everything there is to know about the immune cell engager landscape, including clinical successes, prospective response predictors, and cutting-edge immune cell-based engager therapeutic discoveries.